Organovo is the first company to succesfully print human tissue, and now offer a real product: exVive 3D Human Liver Tissue. With results in less than 1 month companies can send protential blockbuster drugs to be tested by Organovo for only $175,000. Bypassing the old procedure of human trials and FDA approvals, Organovo products can eliminate years and billions of dollars in research and development. Biotech and drug companies can right away find out if a drug has a potential impact, good or bad. Organovo also has plans in developping other tissues that can be tested next year. If more tissue products are released next year you can expect some big moves in ONVO. However, revenues from these products will come in slowly. So ONVO is regarded as a very speculative future growth play.
ONVO as of Dec. 1, 2014
24.56 % short interest
73 million float
ONVO as of Dec. 1, 2014
24.56 % short interest
73 million float